Page last updated: 2024-08-16

thalidomide and abt-199

thalidomide has been researched along with abt-199 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y1
Abdul-Hay, M; Desai, AV; El-Bakkar, H1
Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T1
Chakraborty, R; Lentzsch, S1
Abdallah, AO; Arriola, E; Bowles, KM; Bueno, OF; Coppola, S; Gasparetto, C; Mander, G; Mateos, MV; Morris, L; Ross, JA; Wang, J1

Reviews

4 review(s) available for thalidomide and abt-199

ArticleYear
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases

2022
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide

2015
Novel therapies in low- and high-risk myelodysplastic syndrome.
    Expert review of hematology, 2019, Volume: 12, Issue:10

    Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous

2019
Emerging drugs for the treatment of light chain amyloidosis.
    Expert opinion on emerging drugs, 2020, Volume: 25, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Bridged Bicyclo Compounds, Heterocyclic; Drug Development; Humans; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Sulfonamides; Thalidomide

2020

Trials

1 trial(s) available for thalidomide and abt-199

ArticleYear
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Progression-Free Survival; Sulfonamides; Thalidomide

2021